Shilpa Medicare share news and announcements
NSE: SHILPAMEDBSE: 530549Pharmaceuticals & BiotechnologySmall Cap
Last close ₹864.30up ₹3.50 (0.41%)BSE ₹862.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹860.80.
52-week range of traded prices to 23 Oct 2026
₹259.50Low, 27 Jan 2026₹1,095.00High, 1 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹16,904 Cr637th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 56.9
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 63.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 May 2026
- 6.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.07%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 12.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 10.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 22 May 2026
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 9,55,72541.8% delivered
Shilpa Medicare share news and announcements
754 announcements, routine notices left out, newest first. Page 13 of 16.
Nov 2016
3 Nov · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to announcement dated 02-Nov-2016, regarding "Shilpa Medicare Limited has informed the Exchange that Koanna Healthcare Limited, UK, a wholly owned subsidiary of Shilpa Medicare Limited, INDIA has received marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) for the IMATINIB TABLETS in multiple strengths of 100 mg and 400 mg. The marketing authorization application for this generic product is made through decentralized procedure in 15 EU member states, which involves major European countries like UK, Germany, Netherlands, France, Czech Republic, Belgium, Ireland, Romania etc. Out of 15 member states the first approval is received from UK MHRA. Approvals from remaining member states will follow. ".On basis of above the Company is required to clarify following:1. Impact/relevance of such approval/license to the listed entity;2. Period for which such approval/license is/was valid;The response of the Company is awaited.
Oct 2016
3 Oct · Regulation 44(3) of SEBI (LODR), Reg., 2015
Sep 2016
Aug 2016
Jul 2016
Jun 2016
27 Jun · Board meeting
8 Jun · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to an announcement submitted to the Exchange dated May 30,2016, regarding outcome of meeting of the Board of Directors of the Company held on May 30, 2016 wherein Board of Directors has considered and approved the proposal for acquisition of 100% equity shares of Nu Therapeutics Private Limited (NTPL) in which Shilpa Medicare Limited already holds to the extent of 67.94% equity shares of the NTPL. On basis of above Company is required to clarify following -1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Nature of consideration - whether cash consideration or share swap and details of the same;4. Indicative time period for completion of the acquisition;5. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);6. Brief details of any governmental or regulatory approvals required for the acquisition;The reply from the Company is awaited.
May 2016
Apr 2016
Mar 2016
Feb 2016
11 Feb · Updates
Company has received compliance letter from USFDA for both API manufacturing sites located at Raichur, Karnataka, India (Unit-1: Deosugur Industrial Area, Deosugur, Raichur, Karnataka, India and Unit-2: Raichur Industrial Growth Centre, Chicksugur, Raichur, Karnataka, India).
Jan 2016
Dec 2015
Nov 2015
Oct 2015
29 Oct · Corporate action
Company has fixed Record Date as November 9, 2015 for the purpose of Sub-division of existing equity share of Rs. 2/- each into Two equity shares Re.1/- each.
Sep 2015
Aug 2015
Jul 2015
Jun 2015
12 Jun · Code of Conduct under SEBI(PIT) Reg., 2015
May 2015